Vudalimab

DRUG4 trials

Sponsors

Xencor Inc., Xencor, Inc., Northwestern University, Emory University

Conditions

Advanced Non-small Cell Lung CancerCastration-Sensitive Prostate CarcinomaCervical CarcinomaClear Cell CarcinomaEndometrial CancerLocally Advanced Thyroid Gland Anaplastic CarcinomaMetastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Prostate Adenocarcinoma

Phase 1

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

TerminatedNCT05733351

Emory UniversityCastration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2023-08-03End: 2025-06-12Updated: 2025-09-15

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

CompletedCTIS2023-509644-10-00

Xencor Inc.Advanced Non-small Cell Lung Cancer

Start: 2024-06-27End: 2025-12-29Target: 116Updated: 2025-11-17

Phase 2

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Active, not recruitingNCT05032040

Xencor, Inc.Cervical Carcinoma, Clear Cell Carcinoma, Endometrial Cancer +2

Start: 2022-07-21End: 2025-12-30Target: 170Updated: 2025-02-07

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Active, not recruitingNCT05453799

Northwestern UniversityLocally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma

Start: 2022-07-21End: 2027-07-15Target: 54Updated: 2025-10-17

Related Papers

733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer

Regular and Young Investigator Award Abstracts2022-11-011 citations